Developer docs
API playgroundTry for free, no card

Search company profiles

Canaan Partners

Full company profile

uuid00007b4

Namestring
Canaan Partners
Legal namestring
Canaan
Websiteurl
canaan.com
Company typeenum
Private
Founded yearint
1988
Descriptiontext

Canaan Partners is a private, early-stage venture capital firm founded in 1988 and headquartered in Menlo Park, California, with additional U.S. offices in San Francisco and New York. The firm invests across technology and healthcare at the seed and Series A stages, with approximately 40% of its most recent prior fund (Canaan XII) dedicated to healthcare and biopharma. Its portfolio spans consumer applications (e.g., The RealReal, OpenArt), fintech (LendingClub, RenoFi), enterprise and cloud (Snyk, Sumble, Enterpret), frontier tech (Hermeus, AttoTude, Field AI), and biopharma (Synthekine, Arrakis, Day One, Draig, Vima). The firm has raised $7B across 13 successive early-stage venture capital funds, with the most recent, Canaan XIII, closed at $850M in 2023, bringing total assets under management to $6.8B and cumulative realized outcomes to 73 IPOs and 152 M&A exits.

Canaan generates revenue through standard venture fund economics: recurring management fees on committed and invested capital in its 13 successive funds, supplemented by carried interest on successful exits. The firm does not sell a product or service in the conventional sense; capital deployment to portfolio companies is the primary 'product,' and value-add is delivered through partner-led board support, recruiting networks, go-to-market advice, and ecosystem programs such as Canaan Build (a founder enablement platform) and the Enterprise insights platform. The firm invests where 'science and technology become society,' with active deal flow sourced from the U.S. (West Coast and East Coast), Israel, and Europe.

The investment team is publicly highlighted as a differentiator: 12-year average partner tenure, 40% women representation, 47% immigrants or first generation, and 130 years of combined operating experience. The 16 named General Partners include Brendan Dickinson, Brent Ahrens, Colleen Cuffaro, Deepak Kamra, Felipe Ossio, Hrach Simonian, John Balen, Joydeep Bhattacharyya, Julie Grant, Laura Chau, Maha Ibrahim, Nina Kjellson, Rich Boyle, Stephen Bloch, Tim Shannon, and Wende Hutton. The firm distributes thought leadership through a blog, the WoVen Podcast, partner Substacks, and recurring Women Who Venture community events.

Short descriptiontext

Canaan Partners is a private early-stage venture capital firm founded in 1988 that invests in transformative technology and healthcare companies, managing $6.8B AUM across 13 funds and serving founders in the U.S., Israel, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
early-stage venture capital, seed and series A, biopharma venture investing, technology venture capital, venture capital funds
Industry4 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Early-Stage Private Equity
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Early-stage venture fund management (management fees)
TypeManaged Services
Description

Canaan raises and manages a series of early-stage venture capital funds, generating recurring management fees on committed and invested capital. Has raised $7B across 13 funds, with the most recent fund (Canaan XIII) closed at $850M, bringing total AUM to $6.8B. Approximately 40% of fund XII was dedicated to healthcare investments.

canaan.com
2Carried interest (performance fees)
TypeManaged Services
Description

Standard VC fund economics include carried interest on successful exits. Canaan's 73 IPOs and 152 M&A exits across 37 years demonstrate the realized-gain engine that drives performance-based income alongside recurring management fees.

canaan.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Canaan Build
Description

Canaan's platform for builders/entrepreneurs, accessible via platform.canaan.com/build/

canaan.com
+1 more record
Core offering1 text field

Canaan Partners is an early-stage venture capital firm that raises successive flagship funds and deploys the capital into seed and Series A startups in healthcare/biopharma and technology. The firm has raised $7 billion across 13 funds, with the most recent fund (Canaan XIII) closed at $850 million in 2023 and total AUM of $6.8 billion. Alongside capital, Canaan provides hands-on strategic support, board-level guidance, recruiting help, and a network of operators and executives to portfolio founders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 73 IPOs and 152 M&As as portfolio exits (cumulative, 37 years)
+4 more records
Product overview1 text field

Canaan Partners operates as a unified investment platform offering early-stage venture capital services rather than a multi-product technology stack. Its core offering is venture capital investment management, delivered through a series of flagship funds — including the 12th fund ($800M, 2020) and Canaan XIII ($850M, 2023) — that invest in visionaries with transformative ideas across sectors such as healthcare, technology, and consumer. The funds function as the firm's primary "products," with portfolio support, founder resources, and sector-focused investment teams serving as adjunct services around the capital deployment vehicle.

Product and service2 records
1Canaan XIII fund
CategoryInvestment fund
Description

Canaan's 13th early-stage venture capital fund, raised at $850 million in 2023, deploying capital into visionaries with transformative ideas across the firm's healthcare and technology focus areas. Available to Limited Partners as a fund commitment.

2Canaan XII fund (12th fund)
CategoryInvestment fund
Description

Canaan's 12th early-stage venture capital fund, raised at $800 million in 2020 with approximately 40% dedicated to healthcare investments and ramping up biopharma and de novo company formation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Doorstep (Shashwat Murarka and Sheel Patel)
Strategic tierPortfolio Co-Founders / Strategic RelationshipTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Doorstep is a Canaan-seeded startup founded by Shashwat Murarka and Sheel Patel that developed indoor delivery tracking technology using phone sensors. Canaan led the $8M seed round.

hartfordbusiness.com
Strategic tierHistorical Co-Investment And Acquirer RelationshipsTypeStrategic or Co-development Partner
Description

Historical relationships with key strategic acquirers and technology partners of Canaan's portfolio companies (e.g., DoubleClick acquired by Google; Berkshire Grey acquired by SoftBank via SPAC).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage VC firm with a deep healthcare and technology franchise. Khosla and Canaan co-invested in Hermeus and Draig Therapeutics, reflecting similar frontier-tech and biopharma thesis overlap.

TypeDirect peer
Description

One of the longest-tenured US early-stage VC firms (founded 1911), with comparable AUM scale and a healthcare/technology dual-vertical investment platform. Bessemer and Canaan frequently co-invest in cloud, fintech, and healthcare rounds.

TypeDirect peer
Description

Early-stage-to-growth VC with a similar technology and healthcare thesis. General Catalyst and Canaan co-led Rylo's $85M growth round and frequently co-invest across consumer, fintech, and enterprise stages.

TypeBroad incumbent
Description

Larger, multi-stage VC platform with much greater AUM and broader fund structure. While not a direct early-stage peer, a16z increasingly competes with Canaan in AI infrastructure, consumer, and fintech seed rounds.

TypeDirect peer
Description

Early-stage VC firm with deep-tech and frontier-technology thesis overlap (Hermeus, SpaceX-style bets). Comparable in its high-conviction, founder-led early-stage posture and US-centric investment focus.

TypeDirect peer
Description

Large, diversified US early-stage VC firm with similar broad technology and healthcare mandate and comparable multi-billion-dollar AUM. NEA and Canaan both operate multi-vertical seed-through-growth platforms.

TypeDirect peer
Description

Global early-stage VC firm with comparable technology and consumer mandate, and similar US/Europe/Israel geographic footprint. Lightspeed and Canaan both participate in AI, fintech, and enterprise seed-to-Series B rounds.

TypeDirect peer
Description

Long-established (1972) early-stage VC firm with similar healthcare/digital and technology franchise focus. Canaan and Kleiner Perkins co-invested in Enterpret's $20.8M Series A, and both maintain founder-friendly, multi-stage capital models.

TypeDirect peer
Description

Long-tenured early-stage VC firm (1965) focused on enterprise and consumer technology. Comparable in AUM scale and the practice of leading seed and Series A rounds in enterprise software and consumer categories where Canaan is also active.

TypeDirect peer
Description

Premier early-stage VC firm with comparable vintage, US/Europe footprint, and seed-to-Series A focus on enterprise, consumer, and fintech. Accel and Canaan share the founder-friendly, high-conviction early-stage playbook.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment910 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Canaan Partners

Venture Capital / Early-Stage Private Equitycanaan.com

Canaan Partners is a private early-stage venture capital firm founded in 1988 that invests in transformative technology and healthcare companies, managing $6.8B AUM across 13 funds and serving founders in the U.S., Israel, and Europe.

What Canaan Partners does

Canaan Partners is a private, early-stage venture capital firm founded in 1988 and headquartered in Menlo Park, California, with additional U.S. offices in San Francisco and New York. The firm invests across technology and healthcare at the seed and Series A stages, with approximately 40% of its most recent prior fund (Canaan XII) dedicated to healthcare and biopharma. Its portfolio spans consumer applications (e.g., The RealReal, OpenArt), fintech (LendingClub, RenoFi), enterprise and cloud (Snyk, Sumble, Enterpret), frontier tech (Hermeus, AttoTude, Field AI), and biopharma (Synthekine, Arrakis, Day One, Draig, Vima). The firm has raised $7B across 13 successive early-stage venture capital funds, with the most recent, Canaan XIII, closed at $850M in 2023, bringing total assets under management to $6.8B and cumulative realized outcomes to 73 IPOs and 152 M&A exits.

Canaan generates revenue through standard venture fund economics: recurring management fees on committed and invested capital in its 13 successive funds, supplemented by carried interest on successful exits. The firm does not sell a product or service in the conventional sense; capital deployment to portfolio companies is the primary 'product,' and value-add is delivered through partner-led board support, recruiting networks, go-to-market advice, and ecosystem programs such as Canaan Build (a founder enablement platform) and the Enterprise insights platform. The firm invests where 'science and technology become society,' with active deal flow sourced from the U.S. (West Coast and East Coast), Israel, and Europe.

The investment team is publicly highlighted as a differentiator: 12-year average partner tenure, 40% women representation, 47% immigrants or first generation, and 130 years of combined operating experience. The 16 named General Partners include Brendan Dickinson, Brent Ahrens, Colleen Cuffaro, Deepak Kamra, Felipe Ossio, Hrach Simonian, John Balen, Joydeep Bhattacharyya, Julie Grant, Laura Chau, Maha Ibrahim, Nina Kjellson, Rich Boyle, Stephen Bloch, Tim Shannon, and Wende Hutton. The firm distributes thought leadership through a blog, the WoVen Podcast, partner Substacks, and recurring Women Who Venture community events.

Canaan Partners firmographics

Firmographics
Name
Canaan Partners
Legal name
Canaan
Website
https://canaan.com
Company type
Private
Founded year
1988
Operating status
Operating
Headcount range
251–500 employees
Short description
Canaan Partners is a private early-stage venture capital firm founded in 1988 that invests in transformative technology and healthcare companies, managing $6.8B AUM across 13 funds and serving founders in the U.S., Israel, and Europe.
Ownership category
akta.pro rank

Canaan Partners industry classification

Industry
Product category
Venture Capital / Early-Stage Private Equity
NAICS
Funds, Trusts, and Other Financial Vehicles (525), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks

Keywords

  • Early-stage venture capital
  • Seed and series A
  • Biopharma venture investing
  • Technology venture capital
  • Venture capital funds

Where Canaan Partners is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Canaan Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Early-stage venture fund management (management fees): Canaan raises and manages a series of early-stage venture capital funds, generating recurring management fees on committed and invested capital. Has raised $7B across 13 funds, with the most recent fund (Canaan XIII) closed at $850M, bringing total AUM to $6.8B. Approximately 40% of fund XII was dedicated to healthcare investments.
  2. Carried interest (performance fees): Standard VC fund economics include carried interest on successful exits. Canaan's 73 IPOs and 152 M&A exits across 37 years demonstrate the realized-gain engine that drives performance-based income alongside recurring management fees.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Canaan Partners product offering

Product offering

Core offering

Canaan Partners is an early-stage venture capital firm that raises successive flagship funds and deploys the capital into seed and Series A startups in healthcare/biopharma and technology. The firm has raised $7 billion across 13 funds, with the most recent fund (Canaan XIII) closed at $850 million in 2023 and total AUM of $6.8 billion. Alongside capital, Canaan provides hands-on strategic support, board-level guidance, recruiting help, and a network of operators and executives to portfolio founders.

Product overview

Canaan Partners operates as a unified investment platform offering early-stage venture capital services rather than a multi-product technology stack. Its core offering is venture capital investment management, delivered through a series of flagship funds — including the 12th fund ($800M, 2020) and Canaan XIII ($850M, 2023) — that invest in visionaries with transformative ideas across sectors such as healthcare, technology, and consumer. The funds function as the firm's primary "products," with portfolio support, founder resources, and sector-focused investment teams serving as adjunct services around the capital deployment vehicle.

Differentiator

Problem solved

Functional benefit

Brands

  • Canaan Build: Canaan's platform for builders/entrepreneurs, accessible via platform.canaan.com/build/
  • The WoVen Podcast

Products and services

  • Canaan XIII fund Canaan's 13th early-stage venture capital fund, raised at $850 million in 2023, deploying capital into visionaries with transformative ideas across the firm's healthcare and technology focus areas. Available to Limited Partners as a fund commitment.
  • Canaan XII fund (12th fund) Canaan's 12th early-stage venture capital fund, raised at $800 million in 2020 with approximately 40% dedicated to healthcare investments and ramping up biopharma and de novo company formation.

Quantifiable outcome

  • 73 IPOs and 152 M&As as portfolio exits (cumulative, 37 years)
  • +4 more outcomes

Companies that use Canaan Partners

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Canaan Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Canaan Partners partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered portfolio co-founders / strategic relationship and historical co-investment and acquirer relationships.

  • Doorstep (Shashwat Murarka and Sheel Patel)portfolio co-founders / strategic relationshipStrategic or Co-development Partner · 25 September 2025Doorstep is a Canaan-seeded startup founded by Shashwat Murarka and Sheel Patel that developed indoor delivery tracking technology using phone sensors. Canaan led the $8M seed round.
  • Dropbox / DoubleClick (historical)historical co-investment and acquirer relationshipsStrategic or Co-development PartnerHistorical relationships with key strategic acquirers and technology partners of Canaan's portfolio companies (e.g., DoubleClick acquired by Google; Berkshire Grey acquired by SoftBank via SPAC).

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Canaan Partners competitors and assessment

Company assessment

Direct peers

  • Khosla Ventures: Early-stage VC firm with a deep healthcare and technology franchise. Khosla and Canaan co-invested in Hermeus and Draig Therapeutics, reflecting similar frontier-tech and biopharma thesis overlap.
  • Bessemer Venture Partners: One of the longest-tenured US early-stage VC firms (founded 1911), with comparable AUM scale and a healthcare/technology dual-vertical investment platform. Bessemer and Canaan frequently co-invest in cloud, fintech, and healthcare rounds.
  • General Catalyst: Early-stage-to-growth VC with a similar technology and healthcare thesis. General Catalyst and Canaan co-led Rylo's $85M growth round and frequently co-invest across consumer, fintech, and enterprise stages.
  • Founders Fund: Early-stage VC firm with deep-tech and frontier-technology thesis overlap (Hermeus, SpaceX-style bets). Comparable in its high-conviction, founder-led early-stage posture and US-centric investment focus.
  • NEA (New Enterprise Associates): Large, diversified US early-stage VC firm with similar broad technology and healthcare mandate and comparable multi-billion-dollar AUM. NEA and Canaan both operate multi-vertical seed-through-growth platforms.
  • Lightspeed Venture Partners: Global early-stage VC firm with comparable technology and consumer mandate, and similar US/Europe/Israel geographic footprint. Lightspeed and Canaan both participate in AI, fintech, and enterprise seed-to-Series B rounds.
  • Kleiner Perkins: Long-established (1972) early-stage VC firm with similar healthcare/digital and technology franchise focus. Canaan and Kleiner Perkins co-invested in Enterpret's $20.8M Series A, and both maintain founder-friendly, multi-stage capital models.
  • Greylock Partners: Long-tenured early-stage VC firm (1965) focused on enterprise and consumer technology. Comparable in AUM scale and the practice of leading seed and Series A rounds in enterprise software and consumer categories where Canaan is also active.
  • Accel: Premier early-stage VC firm with comparable vintage, US/Europe footprint, and seed-to-Series A focus on enterprise, consumer, and fintech. Accel and Canaan share the founder-friendly, high-conviction early-stage playbook.

Broad incumbents

  • Andreessen Horowitz (a16z): Larger, multi-stage VC platform with much greater AUM and broader fund structure. While not a direct early-stage peer, a16z increasingly competes with Canaan in AI infrastructure, consumer, and fintech seed rounds.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Canaan Partners social profiles

Digital presence

Canaan Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Canaan Partners leadership team

Management profile

Number of profiles

Profiles18 records

Canaan Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Canaan Partners M&A and investment

M&A and investment

M&A

Investments910 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canaan Partners

What does Canaan Partners do?

Canaan Partners is an early-stage venture capital firm that raises successive flagship funds and deploys the capital into seed and Series A startups in healthcare/biopharma and technology. The firm has raised $7 billion across 13 funds, with the most recent fund (Canaan XIII) closed at $850 million in 2023 and total AUM of $6.8 billion. Alongside capital, Canaan provides hands-on strategic support, board-level guidance, recruiting help, and a network of operators and executives to portfolio founders.

Is Canaan Partners a public or private company?

Canaan Partners is a private company. It is classified as management employee owned and is currently operating.

When was Canaan Partners founded?

Canaan Partners was founded in 1988. It employs 251 to 500 people.

Where is Canaan Partners based?

Canaan Partners is headquartered in San Francisco, United States, in the North America region.

How does Canaan Partners make money?

Two revenue lines are on record. Early-stage venture fund management (management fees) is the primary driver. The others are carried interest (performance fees).

Who are Canaan Partners's main competitors?

Direct peers on record are Khosla Ventures, Bessemer Venture Partners, General Catalyst, Founders Fund, NEA (New Enterprise Associates), Lightspeed Venture Partners, Kleiner Perkins, Greylock Partners and Accel. Andreessen Horowitz (a16z) is listed as a broad incumbent.

Does Canaan Partners have an API?

No public API is recorded for Canaan Partners.

What industry is Canaan Partners in?

Canaan Partners's product category is Venture Capital / Early-Stage Private Equity. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAGAG, Endowment / OCIO-Style Multi-Manager Platforms. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LAVCACanaan Leads USD24m Series A for Nova - LAVCACanaan led a USD24m Series A for Nova, a Brazil-based fintech enabling Pix payments and bill payments via credit cards, with participation from Propel Ventures and follow-on from Canary and Monashees. The round included USD4m in secondary share sales.Brazil JournalA rodada da Nova, que turbina o crédito conectando cartões e contasNova, a fintech, raised $24 million in a funding round led by Canaan, with Propel Ventures participating. The funds will scale its payment wallet, Nova Pay, which lets users pay bills or do Pix with credit cards. The company plans to launch Nova Checkout for online merchants in the first half of next year.The SaaS NewsNova Raises $24M Series ABrazil-based fintech Nova raised $24 million in a Series A round led by Canaan. The funding will enable credit card usage for Pix payments, covering expenses like rent and tuition. The company plans to bridge the gap between traditional credit lines and the Pix ecosystem.LatamlistNova raises $24M Series A led by CanaanNova, a Brazilian fintech, raised $24M in a Series A led by Canaan, with participation from Propel Venture Partners and existing investors. The company, which has surpassed 500,000 downloads and processed about $100M in payments, will use the funds to expand its digital wallet and launch a merchant checkout solution.The PaypersNova raises USD 24 mln Series A to link credit cards to Pix | The PaypersBrazilian fintech Nova raised $24 million in a Series A round led by Canaan. The company connects credit card limits to Pix, letting consumers pay rent and tuition via instant transfers. Pix Automático, introduced in June 2025, extends Pix to recurring bills.Startup ResearcherNova Raises US$24 Million Series ANova, a Brazilian fintech, raised US$24 million in Series A funding led by Canaan with Propel Venture Partners and existing investors. The company, which lets users use existing credit cards for Pix transfers and bill payments, reports over US$12 million in annualized revenue. It plans to connect bank accounts and launch a WhatsApp payment assistant.Dealroom.coNova raises $24M to link credit cards to Brazil's Pix network | Dealroom NewsNova, a Brazilian fintech, raised $24 million in a Series A led by Canaan. The company connects credit card limits to Pix, Brazil's instant-payment network, to cover expenses like rent and tuition. Its success depends on consumer adoption and scalability.Startup ResearcherSetara Biosciences Raises US$90 Million Series A FundingSetara Biosciences raised US$90 million in Series A funding from a syndicate including Deerfield, Canaan, and Regeneron Ventures. The clinical-stage biotech, formed after Jazz acquired Actio, will use the funds to advance its pipeline, including STAR-0871, a TRPV4 inhibitor for CMT2C and overactive bladder. The company plans a Phase 1b study in CMT2C patients in 2027.The Pharma LetterSolstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibodySolstice Oncology raised $225 million in a Series A led by RA Capital Management to advance porustobart, a second-generation CTLA-4 antibody, into neoadjuvant colon cancer treatment. The round also included Canaan Partners, Forbion, and other investors.PR Newswire APACHarbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology TherapySolstice Oncology, a partner of Harbour BioMed, raised $225 million in Series A financing led by RA Capital Management to advance porustobart, a neoadjuvant immuno-oncology therapy. The Phase 2 trial for MSS colon cancer will open for enrollment in Q4 2026, with data expected in H2 2027.